In MS patients, median serum NfL levels [interquartile range] measured by EllaTM were higher than by SimoaTM (13.90 pg/ml [10.73‐18.48] for EllaTMvs. 9.46 pg/ml [6.94‐12.9] for SimoaTM, p < 0.001) (Figure 1A). Here, NEFL is linked to myeloid sarcoma.